Analytical performance of lateral flow immunoassay for SARS-CoV-2 exposure screening on venous and capillary blood samples

Margaret A. Black, Guomiao Shen, Xiaojun Feng, Wilfredo F. Garcia Beltran, Yang Feng, Varshini Vasudevaraja, Douglas Allison, Lawrence Hsu Lin, Tatyana Gindin, Michael G. Astudillo, Diane Yang, Mandakolathur R. Murali, A. John Iafrate, George Jour, Paolo Cotzia, Matija Snuderl

Abstract

Numerous serologic immunoassays have been launched to detect antibodies to SARS-CoV-2, including rapid tests. This study validates the use of a lateral flow immunoassay (LFI) intended for rapid screening and qualitative detection of anti-SARS-CoV-2 IgM and IgG in serum, plasma, and whole blood, comparing results with the gold-standard ELISA. We also seek to establish the value of LFI testing on blood obtained from capillary finger-stick samples. Our results show that the Biolidics LFI kit achieves a clinical sensitivity of 92% at seven days post-PCR diagnosis. Furthermore, capillary blood showed a 93% sensitivity for antibody detection, comparable to venous blood. These findings suggest that LFI provides an opportunity for decentralized rapid testing and longitudinal self-monitoring for SARS-CoV-2 exposure.

Introduction

During the early stages of the COVID-19 pandemic, RT-qPCR served as the primary diagnostic tool for identifying active infections. However, PCR testing requires specialized laboratory infrastructure, invasive nasopharyngeal swabs, and fails to identify individuals who have recovered from past infections. Serological tests, which detect antibodies, fill this diagnostic gap by identifying past exposure and potential immunity.

While Enzyme-Linked Immunosorbent Assays (ELISA) are the laboratory standard for antibody detection, they are time-consuming and require trained personnel. Lateral flow immunoassays (LFIs) offer a rapid, decentralized alternative. This study addresses the critical need for rigorous validation of these rapid tests, specifically evaluating whether they can reliably utilize capillary blood from a finger-stick—a method far more accessible for point-of-care and community screening than traditional venous blood draws.

Methods

The researchers conducted a retrospective validation of the Biolidics 2019-nCoV IgG/IgM Detection Kit (Colloidal Gold). The LFI's performance was benchmarked against an in-house ELISA developed by MGH/Ragon.

The methodology focused on three primary areas:

  1. Matrix Comparison: The LFI was tested across four sample types: serum, plasma, venous whole blood, and capillary finger-stick blood to ensure consistency across media.
  2. Temporal Analysis: Sensitivity was evaluated at two distinct time points: "Day 0" (the day of a positive PCR result) and "Day 7" (seven or more days post-diagnosis).
  3. Observer Verification: To mitigate the subjectivity inherent in visual tests, each LFI result was interpreted by two independent observers.

Datasets

The study utilized samples from 62 patients at NYU Langone Medical Center, categorized into three cohorts:

  • Positive Cohort: 39 patients with RT-qPCR-confirmed SARS-CoV-2.
  • Negative Control Cohort: 24 patients, including 20 archived plasma samples from early 2019 (pre-pandemic) to assess cross-reactivity and 4 samples from March 2020 from PCR-negative patients.
  • Capillary Cohort: 14 recovered COVID-19 patients (18–46 days post-diagnosis) specifically recruited for finger-stick validation.

Key Results

Temporal Sensitivity and Specificity

The study revealed that the timing of the test is paramount. At the time of initial PCR diagnosis (Day 0), sensitivity was only 29%. however, this jumped to 92% at seven or more days post-diagnosis. This confirms that LFIs are most effective as exposure screening tools rather than acute diagnostic tools, as the body requires time to mount a detectable immune response.

Regarding specificity, the LFI achieved 100% for IgG antibodies. IgM specificity was slightly lower at 92%, with some false positives observed in pre-COVID-19 samples. This suggests that IgG is the more dependable marker for confirming prior exposure.

Capillary vs. Venous Blood

A primary finding of the study was the high performance of capillary blood. Finger-stick samples from recovered patients showed a 93% sensitivity for antibody detection. Statistical analysis showed no significant difference in performance between the LFI and ELISA at Day 0 or Day 7 (p=1.00), with the minor exception of IgM detection at Day 7 (p=0.04).

Matrix Consistency

Results were consistent across plasma and whole blood. This is a significant practical finding, as it suggests laboratories can bypass the time-consuming step of centrifuge-separating plasma, further accelerating the testing pipeline.

Discussion and Limitations

The validation of finger-stick capillary blood for LFI testing opens the door for decentralized, point-of-care, and potentially self-administered testing. The strong correlation between positive LFI results and high antibody titers in ELISA suggests that these rapid tests effectively identify individuals with robust immune responses.

However, several limitations remain:

  • Sample Size: The capillary validation cohort was small (n=14), requiring larger studies for broader confirmation.
  • Immunity vs. Exposure: The presence of antibodies, while indicative of exposure, does not yet strictly guarantee protective immunity against reinfection.
  • Kinetic Variability: The researchers noted significant inter-individual variability in antibody production, even among household members with similar symptoms.
  • Subjectivity: Because LFIs rely on visual interpretation of faint bands, future iterations might benefit from AI-assisted image analysis to eliminate human error.

Conclusion

The Biolidics 2019-nCoV IgG/IgM Detection Kit demonstrates clinical performance comparable to ELISA, particularly when administered at least one week after symptom onset or diagnosis. The confirmation that capillary blood provides similar sensitivity to venous blood supports the transition toward more accessible, community-based screening and longitudinal monitoring of SARS-CoV-2 exposure.

Summary updated

Abstract

Abstract Objectives Numerous serologic immunoassays have been launched to detect antibodies to SARS-CoV-2, including rapid tests. Here, we validate use of a lateral flow immunoassay (LFI) intended for rapid screening and qualitative detection of anti-SARS-CoV-2 IgM and IgG in serum, plasma, and whole blood, and compare results with ELISA. We also seek to establish the value of LFI testing on blood obtained from a capillary blood sample. Methods Samples collected by venous blood draw and capillary finger stick were obtained from patients with SARS-CoV-2 detected by RT-qPCR and control patients negative for SARS-CoV-2. Samples were tested with the 2019-nCoV IgG/IgM Detection Kit (Colloidal Gold) lateral flow immunoassay, and antibody calls were compared with results obtained by ELISA. Results The Biolidics LFI kit shows clinical sensitivity of 92% at 7 days after PCR diagnosis of SARS-CoV-2 on venous blood. Test specificity was 92% for IgM and 100% for IgG. There was no significant difference in detecting IgM and IgG with Biolidics LFI and ELISA at D0 and D7 (p=1.00), except for detection of IgM at D7 (p=0.04). Finger stick whole blood of SARS-CoV-2 patients showed 93% sensitivity for antibody detection. Conclusions Clinical performance of Biolidics 2019-nCoV IgG/IgM Detection Kit (Colloidal Gold) is comparable to ELISA and showed consistent results across different sample types. Furthermore, we show that capillary blood obtained by finger stick shows similar sensitivity for detecting anti-SARS-CoV-2 IgM and IgG antibodies as venous blood samples. This provides an opportunity for decentralized rapid testing in the community and may allow point-of-care and longitudinal self-testing for the presence of anti-SARS-CoV-2 antibodies.
BibTeX
@article{black2021analytical,
  author = {Margaret A. Black and Guomiao Shen and Xiaojun Feng and Wilfredo F. Garcia Beltran and Yang Feng and Varshini Vasudevaraja and Douglas Allison and Lawrence Hsu Lin and Tatyana Gindin and Michael G. Astudillo and Diane Yang and Mandakolathur R. Murali and A. John Iafrate and George Jour and Paolo Cotzia and Matija Snuderl},
  title = {{Analytical performance of lateral flow immunoassay for SARS-CoV-2 exposure screening on venous and capillary blood samples}},
  journal = {Journal of Immunological Methods},
  year = {2021},
  url = {https://openreview.net/forum?id=6WOlMAPe85},
}
Figure